Stock Alert: ZIOPHARM Oncology, Incorporated (UTC:ZIOP)

Analysts reviewing ZIOPHARM Oncology Inc have recently updated their recommended buy/sell ratings and price targets on the stock. These analysts and investment firms use various valuation methods to decide a price target for a stock. They now have a United States dollars 23 price target on the stock.

06/02/2016 - Raymond James began new coverage on ZIOPHARM Oncology Inc giving the company a " rating.

08/10/2016 - ZIOPHARM Oncology Inc was upgraded to " by analysts at Wells Fargo. (UTC:ZIOP) is performing 28.79%. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company.

To analyze a stock, one should look for Upgrades and Downgrades of a stock.

The 1 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 23.00, with a high estimate of 23.00 and a low estimate of 23.00. According to their predictions High & Low revenue estimates are 2 Million and 1.46 Million respectively.

Zacks Investment Research also rated the stock with a value of 2.5. Looking over the ZIOP ranking chart, the ZIOP got 1 analyst recommendation as a Buy security in previous month pool in contrast with 1 analyst gave buy ratings at this month.

ZIOPHARM Oncology, Inc. closed its last trading session at $6.47 with the loss of -2.94%. (NASDAQ:ZIOP) has 128.90 million outstanding shares among them 127.91 million shares have been floated in market exchange. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus the company showed an Earnings Surprise of 0 Percent. The stock traded with the volume of 1.97 Million shares in the last trading session. Current price level places the company's stock about -41.75% from the 52-week high and 17.41% away from the 52-week low. Current price places the company's stock -19.11% away from its 200-day simple moving average, 5.04%, away from the 50-day average and also 6.17% away from 20-day average. The company saw 1.97 million shares trade hands over the course of the day.

The Stock now has the market capitalization of $899.31 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 4.17% and monthly volatility of 4.42% respectively. The Moving Average SMA50 is 12.88% while SMA200 is 16.63%.

ZIOPHARM Oncology, Inc. (UTC:ZIOP) is now showing its ROA (Return on Assets) of -139.8%.

In the trailing 12 months period, return on assets ratio of the Company was -139.80% and return on equity ratio was 595.10% while its return on investment ratio was 213.90%. The stock now shows its YTD (Year to Date) performance of 28.79 percent while its Weekly performance value is 6.33%. The stock is performing 2.3% year to date.

01/14/2016 - ZIOPHARM Oncology Inc had its " rating reiterated by analysts at JP Morgan. Given that its average daily volume over the 30 days has been 1.48 million shares a day, this signifies a pretty significant change over the norm.

The stock now has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. ZIOP has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 11.09 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.